SMITHKLINE BEECHAM BIOLOG innovation strategy

Patent filings in countries

#	Country	Total Patents
#1	United Kingdom	498
#2	Australia	197
#3	WIPO (World Intellectual Property Organization)	192
#4	Canada	150
#5	EPO (European Patent Office)	130
#6	United States	119
#7	China	96
#8	South Africa	80
#9	Israel	79
#10	Poland	63
#11	Czechia	62
#12	Hungary	61
#13	Argentina	58
#14	Brazil	58
#15	Norway	41
#16	Mexico	37
#17	Hong Kong	36
#18	New Zealand	25
#19	Taiwan	22
#20	Morocco	13
#21	Malaysia	13
#22	Singapore	12
#23	Slovakia	11
#24	Republic of Korea	10
#25	Bulgaria	8
#26	Portugal	8
#27	Cyprus	7
#28	Finland	7
#29	Gulf Cooperation Council	7
#30	Ireland	7
#31	African Intellectual Property Organization	7
#32	Peru	7
#33	Algeria	6
#34	Uruguay	6
#35	EAPO (Eurasian Patent Organization)	4
#36	Japan	4
#37	Colombia	3
#38	Egypt	3
#39	Slovenia	3
#40	African Regional Industrial Property Organization	2
#41	Indonesia	2
#42	Ecuador	1
#43	Yugoslavia (Serbia and Montenegro)	1

#	Technology
#1	Medical preparations
#2	Therapeutic chemical compounds
#3	Peptides
#4	Microorganisms
#5	Climate change adaptation technologies
#6	Unspecified technologies
#7	Analysing materials
#8	Measuring microorganism processes
#9	Medical purpose containers
#10	Foundations and excavations

Publication	Filing date	Title
GB0614254D0	2006-07-18	Vaccine
US2005214285A1	2004-12-07	Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses
US2005031638A1	2004-07-27	Vaccine
US2004213806A1	2004-05-12	Salmonella typhi vaccine compositions
US2005002958A1	2004-02-27	Vaccines
AU2003271337A1	2003-12-17	Vaccine composition
US2005033022A1	2003-10-16	Fusion proteins comprising HIV-1 Tat and/or Nef proteins
US2003157129A1	2003-03-07	Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US2003147906A1	2002-12-18	Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of lgE, antagonists thereof, and their therapeutic uses
US2003170229A1	2002-11-26	Vaccine
US2003133944A1	2002-11-18	Vaccine composition against malaria
US2003219453A1	2002-11-06	Vaccines
US2003049268A1	2002-08-20	Novel composition
US2003022304A1	2002-08-13	Vaccine composition
GB0213628D0	2002-06-13	Novel compounds
AU2962502A	2001-12-07	Novel compounds
WO0228426A1	2001-10-01	Split enveloped virus preparation
TWI311563B	2001-09-21	Method for production a stable,immunogenic hepatitis b vaccine without trace of thiomersal
WO0250103A2	2001-09-18	Tumour-related antigens
US2002054884A1	2001-09-13	Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate